Latest Cancer stem cell Stories
Johns Hopkins scientists say a previously known but little studied chemical compound targets and shuts down a common cancer process.
CAMBRIDGE, Mass., Jan.
In recent years, non-hematopoietic effects of erythropoietin (EPO), via its binding to the EPO receptor in non-hematopoietic tissues, including cancerous tissues, has been reported by many different laboratories worldwide.
Jacco van Rheenen, Ph.D., of the Hubrecht Institute in The Netherlands has been named the winner of the 8th Annual STEM CELLS Young Investigator Award for his investigation on how healthy and
A team of scientists, led by principal investigator Paul S. Mischel, MD, a member of the Ludwig Institute for Cancer Research and professor in the Department of Pathology at the University of California, San Diego School of Medicine, has found that brain cancer cells resist therapy by dialing down the gene mutation targeted by drugs, then re-amplify that growth-promoting mutation after therapy has stopped.
Scientists and surgeons at Princess Margaret Cancer Centre have discovered a promising new approach to treating colorectal cancer by disarming the gene that drives self-renewal in stem cells that are the root cause of disease, resistance to treatment and relapse.
- A poem in which the author retracts something said in an earlier poem.